Therefore, blocking the interactions of MTG16 (or MTG16 fusion proteins) with the wild-type transcription factors, such as E-proteins, or strengthening the interactions of wild-type MTG16 with E-protein-containing leukemia fusion proteins, such as E2A-PBX1, may be considered for the treatment of the related diseases. The gene discussed is CBFA2T3; the disease is leukemia.